Therapeutic Approach

Archive: November, 2016

Ritter Pharmaceuticals, Inc. to Present at the 9th Annual LD Micro Main Event on December 7, 2016

Los Angeles, California, November 28, 2016 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”) develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, is being developed as potentially the first FDA-approved treatment for lactose intolerance. The Company announced today that it will be […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update

LOS ANGELES (November 7, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the third quarter ending September 30, 2016. Recent Highlights Completed last patient dosing […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD